Inventiva S.A. — Company profile
Healthcare · Biotechnology · France
Last price 3.73 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 882.39M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-β, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Details
| Name | Inventiva S.A. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 87 |
| Founded | 2011 |
| Ipo Date | 2020-07-10 |
| Ceo | Andrew Obenshain |
| Country | France |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| Ipo Price | 14.40 |
| Isin | US46124U1079 |
| Cusip | 46124U107 |
| Cik | 1756594 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Andrew Obenshain | Chief Executive Officer |
| Dr. Pierre Broqua Ph.D. | Co-Founder |
| Jean Volatier | Executive Vice President Finance and Corporate Social Responsibility |
| Dr. Martine Zimmermann Pharm.D. | Executive Vice President of Regulatory Affairs and Quality Assurance and Head of Regulatory Affairs |
| Jason A. Campagna M.D., Ph.D. | President of Research and Development and Chief Medical Officer |
| Axel-Sven Malkomes | Chief Financial Officer |
| Christopher Benecchi M.B.A. | Chief Operating Officer |
Contact
| Address | 50 rue de Dijon, Daix, 21121, France |
| Phone | 33 3 80 44 75 00 |
| Website | https://inventivapharma.com |